Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Alterations”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06885840
What this trial is testing

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 100
Early research (Phase 1)WithdrawnNCT05120960
What this trial is testing

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Who this might be right for
Brain Tumor
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Not applicableStudy completedNCT05154344
What this trial is testing

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

Who this might be right for
MET AlterationsNon Small Cell Lung CancerMETex14 Mutations
Intergroupe Francophone de Cancerologie Thoracique 182
Early research (Phase 1)Ended earlyNCT02228811
What this trial is testing

DCC-2701 in Participants With Advanced Solid Tumors

Who this might be right for
Locally Advanced TumorsMetastatic Solid TumorsCancers With MET Genomic Alterations+1 more
Deciphera Pharmaceuticals, LLC 44
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Early research (Phase 1)Study completedNCT03457532
What this trial is testing

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

Who this might be right for
Advanced Solid Tumor
Haihe Biopharma Co., Ltd. 177
Testing effectiveness (Phase 2)Study completedNCT02544633
What this trial is testing

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Who this might be right for
Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. 68
Testing effectiveness (Phase 2)UnknownNCT04647838
What this trial is testing

Tepotinib in Solid Tumors Harboring MET Alterations

Who this might be right for
Solid TumorMET Exon 14 Skipping MutationMET Amplification
Chungbuk National University Hospital 100
Testing effectiveness (Phase 2)WithdrawnNCT05567055
What this trial is testing

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Who this might be right for
Non-small Cell Lung Cancer
Timothy Burns, MD, PHD
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Large-scale testing (Phase 3)Looking for participantsNCT06439225
What this trial is testing

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Prostate Cancer
Canadian Cancer Trials Group 236
Testing effectiveness (Phase 2)Study completedNCT02750215
What this trial is testing

Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Who this might be right for
Malignant Non-small Cell Neoplasm of Lung Stage IV
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01524926
What this trial is testing

CREATE: Cross-tumoral Phase 2 With Crizotinib

Who this might be right for
Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more
European Organisation for Research and Treatment of Cancer - EORTC 582
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Testing effectiveness (Phase 2)Active Not RecruitingNCT02864992
What this trial is testing

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Who this might be right for
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV
EMD Serono Research & Development Institute, Inc. 337
Not applicableLooking for participantsNCT05376891
What this trial is testing

Met Non Small Cell Cancer Registry (MOMENT)

Who this might be right for
Cancer
EMD Serono Research & Development Institute, Inc. 700
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)Study completedNCT02034981
What this trial is testing

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

Who this might be right for
Hematologic CancersSolid TumorsMetastatic Cancer
UNICANCER 246
Testing effectiveness (Phase 2)Looking for participantsNCT06669117
What this trial is testing

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Who this might be right for
Solid TumorMET Alteration
Pierre Fabre Medicament 140
Next Page